• Fri, October 30, 2026
  • Thu, October 29, 2026

Oct, 29th 2026 Edge Report for Butterfly Network, Inc. (BFLY)

BFLY exhibits disruptive tech patterns with high burn rates. Market value now hinges on transitioning to SaaS revenue and managing macro risks.

Date: Oct 30th, 2026
Butterfly Network, Inc. (BFLY)
Sector: X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS

Current Price: $7.425
1 SOTP Price: $$
2 Rating: $$ (0.0 sell - 10.0 buy)
1 The SOTP valuation is derived by assigning a 5x multiple to the projected 12-month ARR (Annual Recurring Revenue) from subscriptions, adding a discounted cash flow (DCF) value for the hardware pipeline, and applying a premium for the proprietary 'Ultrasound-on-a-Chip' IP portfolio. This assumes a 20% growth in the active subscriber base. - Main catalysts: SaaS Recurring Revenue Growth, Intellectual Property (IP) Value of CMOS sensors, Installed Base Monetization
2 The rating reflects a 'Speculative Buy'. The underlying technology is a generational leap in diagnostics and the trade data shows strong institutional interest during catalysts. However, the score is capped by persistent cash burn and the high volatility seen in the 2026 price action. It is a high-conviction technology play but a high-risk financial play.


Executive Summary

The behavioral profile of BFLY is characteristic of a 'disruptive tech' asset moving through a speculative cycle. From late 2025 to mid–2026, the stock exhibited a classic momentum climb, culminating in the June 18 event where volume expanded by 10x the average. This indicates a narrative shift from 'existence risk' to 'growth potential'.

Investor psychology is currently caught between FOMO (fear of missing the pivot to profitability) and capitulation (fear of further dilution). The decline from 10.05 to 7.425 reflects a 'cooling off' period where the market is demanding concrete revenue growth over theoretical TAM. Narrative contagion via social platforms likely drove the August peak, while the current slide suggests a more strategic, institutional re-evaluation.

Macroeconomically, the stock is highly sensitive to inflation expectations. Because BFLY relies on future cash flows, a 'higher for longer' interest rate environment increases the discount rate, compressing the valuation. Recession fears further complicate the outlook, as hospital capital expenditure (CapEx) budgets are typically the first to be cut during economic contractions.

Regarding cash flow: The primary source of cash is hardware sales and an increasing share of recurring SaaS revenue. However, burn remains high due to aggressive ®&D and sales expansion. To improve this, BFLY must aggressively transition from a hardware-first to a software-first model, increasing the LTV (Lifetime Value) of each customer while lowering the CAC through AI-driven automated sales. The current price consolidation suggests the market is waiting to see if the 'burn rate' is decelerating in tandem with the revenue growth.

    Important Take-Aways
  • Market narrative has shifted from existence risk toward growth potential.
  • Valuation is highly sensitive to inflation and hospital capital expenditure budgets.
  • Strategic necessity to transition from a hardware-first to a software-first model.
  • Current price consolidation reflects market scrutiny of the company's burn rate.


Financial Picture

The short pressure on BFLY is represented in the heatmap from the last ~50 weeks as (short vol / total vol).


Active Competitors

SymbolPriceContact
• GE HealthCareGEHC$76.61 $$ 11 Contacts
Possesses massive installed base and deep institutional trust. Their Vscan series competes directly on portability, and their ability to bundle ultrasound with larger hospital contracts is a structural threat.
• Philips HealthcarePHG$27.13 $$ 1 Contacts
The Lumify system is a direct competitor in the handheld space. Philips' strength in integrated health informatics could allow them to wrap ultrasound into a broader diagnostic ecosystem more effectively than Butterfly.
• Mindray300963.SZ$N/A
Aggressive pricing strategies in emerging markets. As Butterfly seeks global growth, Mindray's ability to undercut on hardware price while providing 'good enough' quality poses a risk to market share in Asia and Africa.

Potential Partners

SymbolPriceContact
• NVIDIA CorporationNVDA$213.17 $$ 2 Contacts
A partnership for edge-computing AI optimization. Integrating NVIDIA's Clara platform could allow Butterfly to run more complex diagnostic models locally on the device without relying on cloud latency.
• Amazon Web ServicesAMZN$245.26 $$ 4 Contacts
Expanding the cloud infrastructure for 'Butterfly Cloud'. A deep integration with AWS HealthLake would simplify the storage and sharing of ultrasound data across disparate health systems.
• CVS HealthCVS$90.18 $$ 3 Contacts
Deploying handheld ultrasound in retail clinics. This would shift the company's revenue model further toward decentralized diagnostics and consumer-facing healthcare.

Recent Events

  • [2026-06-18] Q3 2026 Volume Surge / Catalyst Event
    A massive spike in trading volume on 2026-06-18 (63M+ shares) and subsequent price jump from 6.08 to 8.96 suggests a major regulatory approval or strategic partnership announcement.
  • [2026-08-10] Price Peak and Consolidation
    The stock reached a local peak of 10.05 on 2026-08-10. The subsequent decline to the current 7.425 indicates a transition from momentum-driven speculation to fundamental valuation.
  • [2026-10-29] October 2026 Volatility
    Recent price action shows significant intraday swings, indicating a struggle between strategic accumulation and short-term profit taking after the Summer rally.


AI Improvement Use Cases

Let Us Develop Your AI Integrations! Request Quantified Reports AI Services Here!
  • Autonomous Clinical Documentation Implementing AI to transcribe the clinical context of a scan and automatically populate the Electronic Health Record (EHR) based on the image findings.
    Impact: Significant reduction in administrative burden for clinicians, removing a primary barrier to widespread device adoption.
  • AI-Driven Lead Scoring for B2B Sales Applying predictive analytics to healthcare system procurement data to identify facilities with high POCUS (Point-of-Care Ultrasound) needs but low current penetration.
    Impact: Increased sales efficiency and lower customer acquisition costs (CAC) by targeting high-probability conversion accounts.
  • Automated Billing and Claims Processing Using AI to map captured ultrasound images and clinical notes to specific CPT codes for insurance reimbursement.
    Impact: Accelerated revenue cycle and reduced claim denial rates for healthcare providers using Butterfly devices.


Potential Growth Drivers

  • AI-Guided Image Acquisition: Integrating real-time computer vision models to guide non-expert users in placing the ultrasound probe correctly to capture diagnostic-quality images.
    Impact: Expansion of the Total Addressable Market (TAM) from specialized sonographers to general practitioners and emergency first responders.
  • Automated Triage and Anomaly Detection: Deploying AI models that can automatically flag abnormal findings (e.g., pleural effusion or cardiac ejection fraction anomalies) before a radiologist reviews the scan.
    Impact: Increased clinical value proposition for the 'Ultrasound-as-a-Service' model, justifying higher subscription premiums.
  • Predictive Maintenance via Telemetry: Using machine learning to analyze device hardware telemetry to predict probe failure or battery degradation.
    Impact: Reduction in warranty costs and improved customer retention through proactive hardware replacement.


Final Projections

PriceConvictionProbabilityCatalystsRisks
$7.1570%65%Short-term mean reversion
End-of-month window dressing
Further breakdown of support levels at 6.80
Macro volatility
$8.560%55%Q4 earnings report
New AI feature release
Equity offering for capital raise
Regulatory delays
$9.250%50%Expanded adoption in retail clinics
Improved EBITDA margins
Competitive pricing war from GE/Philips
Economic recession
$1140%40%Achievement of cash-flow break-even
Major government health contract
Failure to scale SaaS revenue
Significant hardware defects
$1530%30%Global dominance in POCUS
Acquisition target for a MedTech giant
Technological obsolescence
Chronic undercapitalization


Data Citations, Disclosures and Disclaimers

    Data Sources
  • Yahoo Finance Company profile and basic financial metrics including revenue and employee count.
  • SEC EDGAR 10-Q filing used for analysis of cash burn, liquidity, and structural growth opportunities.
  • Trade Data Set Analysis of volume spikes, price volatility, and short-interest trends from 2025-10-31 to 2026-10-29.
    Disclosures and Disclaimers
  • The analyst holds no direct position in BFLY at the time of writing.
  • This report is for institutional informational purposes and does not constitute a solicitation or recommendation, to buy or sell securities.
  • Investment in equities involves significant risk. Past performance is not indicative of future results. Projections are based on current market conditions and are subject to change without notice.

QR - QuantifiedReports
Crunching the numbers, so you don't have to. We are utilizing AI extensively to produce the most accurate and predictive stock reports, you can find.

Like: 👍